- Home
- SIBN vs ALT Comparison
SIBN vs ALT Comparison
Compare SIBN & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIBN
- ALT
- Stock Information
- Founded
- SIBN 2008
- ALT 1997
- Country
- SIBN United States
- ALT United States
- Employees
- SIBN N/A
- ALT N/A
- Industry
- SIBN Medical/Dental Instruments
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- SIBN Health Care
- ALT Health Care
- Exchange
- SIBN Nasdaq
- ALT Nasdaq
- Market Cap
- SIBN 547.3M
- ALT 472.3M
- IPO Year
- SIBN 2018
- ALT N/A
- Fundamental
- Price
- SIBN $14.04
- ALT $5.32
- Analyst Decision
- SIBN Strong Buy
- ALT Strong Buy
- Analyst Count
- SIBN 6
- ALT 8
- Target Price
- SIBN $24.50
- ALT $21.00
- AVG Volume (30 Days)
- SIBN 370.2K
- ALT 3.0M
- Earning Date
- SIBN 05-05-2025
- ALT 05-08-2025
- Dividend Yield
- SIBN N/A
- ALT N/A
- EPS Growth
- SIBN N/A
- ALT N/A
- EPS
- SIBN N/A
- ALT N/A
- Revenue
- SIBN $167,178,000.00
- ALT $20,000.00
- Revenue This Year
- SIBN $18.52
- ALT N/A
- Revenue Next Year
- SIBN $16.36
- ALT N/A
- P/E Ratio
- SIBN N/A
- ALT N/A
- Revenue Growth
- SIBN 20.37
- ALT N/A
- 52 Week Low
- SIBN $11.70
- ALT $5.14
- 52 Week High
- SIBN $19.16
- ALT $11.16
- Technical
- Relative Strength Index (RSI)
- SIBN 33.41
- ALT 39.42
- Support Level
- SIBN $13.80
- ALT $5.60
- Resistance Level
- SIBN $15.40
- ALT $6.16
- Average True Range (ATR)
- SIBN 0.58
- ALT 0.35
- MACD
- SIBN -0.12
- ALT 0.01
- Stochastic Oscillator
- SIBN 12.90
- ALT 17.65
About SIBN SI-BONE Inc.
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.